Prajapati S, Goswami K, Patal A. Synthesis and characterisation of 4-Aryl thiazole ring system and its antimicrobial activity. Int J Pharma Bio Sci 2013; 4(1): 803-8.
Alaraji YH, Shneine JK, Ahmed ANAA. Synthesis, characterization, and antibacterial activity of new Schiff’s bases with 1,2,4-triazole moiety. J Sci 2015; 5(5): 293-9.
Abdulrasool MM, Jawad AH, Shneine JK. Synthesis, characterization and evaluation of biological activity of new heterocyclic compounds containing 1,2,4-triazole and 1,3,4-thiadiazole rings. Int J Appl Sci Technol 2012; 2(10): 155-64.
Arul K, Smith K. In silico design, synthesis and in vitro anticancer evaluation of some novel 1,2,4-triazole derivatives. Experiment 2014; 21(1): 1439-52.
Baviskar B, Khadabadia S, Deore S, Shiradkar M. Synthesis of clubbed triazolyl indeno [1, 2-C] isoquinolines as a novel anticancer agent. Pharm Sin 2012; 3(1): 24-30.
Mandal SK, Saha D, Jain VK, Jain B. Synthesis and antitubercular activity of some triazole derivatives of propyl gallate. Int J Pharm Sci Res 2010; 1: 465-73.
Mali R, Somani R, Toraskar M, Mali K, Naik P, Shirodkar P. Synthesis of some antifungal and anti-tubercular 1,2,4-triazole analogues. Int J Chemtech Res 2009; 1: 168-73.
Maste MM, Ainapure R, Patil P, Bhat A. Triazolone and their derivatives for anti-tubercular activities. Asian J Res Chem 2011; 4(7): 1050-4.
Singh R, Singh D. Novel synthetic approach to some new 1,2,4- triazolothiadiazines and 1,2,4-triazolothiadiazinones and their anti-inflammatory activities. Int J Chemtech Res 2009; 1(4): 1239-43.
Ilango K, Valentina P. Synthesis and biological activities of novel 1, 2, 4-triazolo-[3, 4-b]-1, 3, 4-thiadiazole. Pharma Chem 2010; 2(2): 16-22.
Kharb R, Sharma PC, Bhandari A, Shaharyar M. Synthesis, spectral characterization and anthelmintic evaluation of some novel imidazole bearing triazole derivatives. Der Pharmacia Lett 2012; 4(2): 652-7.
Padmaja A, Rajasekhar C, Muralikrishna A, Padmavathi V. Synthesis and antioxidant activity of disubstituted 1, 3, 4-oxadiazoles, 1, 3, 4-thiadiazoles and 1, 2, 4-triazoles. J Chem Pharm Res 2012; 4(1): 294-302.
Sancak K, Ünver Y, Ünlüer D, et al. Synthesis, characterization, and antioxidant activities of new trisubstituted triazoles. Turk J Chem 2012; 36(3): 457-66.
Hameed AA, Hassan F. Synthesis, characterization and antioxidant activity of some 4-amino-5-phenyl-4h-1, 2, 4-triazole-3-thiol derivatives. Int J Appl 2014; 4: 202-11.
Katritzky AR, Ramsden CA, Joule JA, Zhdankin VV. Reactivity of Heterocycles: Reactivity of Five-membered rings with Two or More Heteroatoms. Reactivity of Heterocyclic Chemistry. (3rd ed). Oxford: Elsevier. 2010; pp. 473-605.
Kumar R, Yar MS, Chaturvedi S, Srivastava A. Triazole as pharmaceuticals potentials. Int J Pharm Tech Res 2013; 5(4): 1844-69.
Saini MS, Dwivedi J. Synthesis and biological significances of 1, 2, 4-triazole and its derivatives: A review. Int J Pharm Sci Res 2013; 4(8): 2866.
da Silva FdC, do Carmo Cardoso MF, Ferreira PG, et al. Biological Properties of 1H-1,2,3-and 2H-1,2,3-Triazoles.Chemistry of 1,2,3-triazoles: 1st ed . Berlin: Heidelberg: Springer-Verlag. 2014; pp. 117-165..
Saikia B, Barua NC, Saikia PP, et al. 1,2,3-Triazole Containing Artemisinin Compounds and Process for Preparation Thereof. US9006467, 2015.
Ramasamy K, Tam R, Averett D. Monocyclic L-nucleosides, analogs and uses thereof. US6642206, 2003.
Heston , Warren DW, Cramer H. Compounds which bind PSMA and uses thereof. WO2006093991, 2007.
Beusker PH, De Groot FMH. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation. US8158590, 2012.
Nara E. Medicinal compositions having improved absorbability. US20040053972, 2001.
Miller M J, Moraski G C, Stefely J. Anti-cancer compounds, synthesis thereof, and methods of using same. US8268874, 2012.
Madadi N R, Penthala N R, Crooks P, Maddukuri L, Eoff R. Disubstituted triazole analogs. US9938246, 2018.
Kohn E C, Liotta L A, Felder C C. 1,2,3-triazole and imidazole compounds and their antitumor use. CA2136356, 2006.
Friebe W-G, Reiff U, von Hirschheydt T, Voss E. Triazole derivatives. US7288557B2, 2007.
Karmali RA. Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate. US8877785, 2014.
Cheng H, Cui J J, Hoffman J E, et al. Triazolopyrazine derivatives useful as anti-cancer agents. EA016204, 2012.
Demko Z, Borella C, Chen S, Sun L. Compounds for the treatment of proliferative disorders. US9175022, 2015.
Naito K, Furuya S, Tasaka A, Ban T. Compounds for the treatment of proliferative disorders. US9175022, 2004.
Bossenmaier B, Friebe W-G, Georges G, Rueth M, Voss E. Pentafluorosulfanyl compounds. US7235574, 2005.
Cogan D, Goldberg D R, Hammach A, Netherton M R, Aungst R. Triazole compounds. US7511042, 2009.
Do S, Goldsmith R, Heffron T, et al. Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use. US9309265, 2016.
Frost P, Discafani-Marro C M. Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer. CA2380904, 2009.
Wissner A, Tsou H-R, Floyd M, Johnson B, Overbeek-Klumpers E. Overbeek-Klumpers, E. 3-cyanoquinolines as inhibitors of EGF-R and HER2 kinases. US20030149056, 2003.
Norris D J, DeLucca G V, Gavai A V, Lee F Y, Tokarski J S. Tricyclic compounds as anticancer agents. US10112941, 2018.
Boman E, Ernst J, Montalban A G, et al. Heteroaryl derivatives as cytokine inhibitors. WO2008021388, 2007.
Hale M R, Maltais F. Triazole-derived kinase inhibitors and uses thereof. US6962936, 2005.
Hupe D. 5-amino or substituted amino 1,2,3-triazoles useful as antimetastatic agents. US5045543, 1991.
Dorsch D, Wucherer-Plietker M, Mueller T J J, Merkul E. 3-(1,2,3-triazol-4-yl)pyrrolo[2,3-b]pyridine derivatives. US8541584, 2013.
Cogan D A, Hao M-H, Quian K C, Swinamer A D. Cytokine inhibitors. US7569568, 2009.
Hoekstra W J, Schotzinger R J, Rafferty S W. Metalloenzyme inhibitor compounds. US8623892, 2014.
Kohn E C, Liotta L A. Therapeutic application of an anti-invasive compound. US5132315, 1992.